BioS: a next generation treatment for acute respiratory distress syndrome (ARDS)
| Reference number | |
| Coordinator | in2cure AB |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | May 2022 - October 2024 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2021 |
Important results from the project
BioS has been studied and its groundbreaking properties published in Nature Communications. In various models, BioS has indicatively shown safety and clinical effect at relevant dose. The ARDS (Acute respiratory distress syndrome) indication proved to be too broad & complex. The plan was instead focused on the possibility of preventing the development of ARDS. Systemic administration was prioritized. BioS was judged to be a suitable drug candidate based on parameters e.g. manufacturing, regulatory path and commercial interest.
Expected long term effects
Transient Pharma can now begin the development of a drug candidate suitable for treating serious inflammatory diseases. They are a major threat to health and cause many deaths and high costs. According to the WHO, 3 out of 5 people die due to chronic inflammatory diseases. Inflammatory diseases with high medical need that can potentially be treated with BioS include heart disease, arthritis, sepsis, ARDS, Behçet´s disease, Crohn´s disease, ulcerative colitis and mucositis.
Approach and implementation
Each partner was responsible for implementing and reporting their respective activities. The WPs were split per partner; could therefore be carried out independently. During implementation, the orientation and thus activities and budget have been optimized based on new data, in dialogue with Vinnova. The collaboration with the partner from Region Skåne has entailed certain challenges, perhaps due to differences in culture of companies and public sector for reporting of results, data and costs.